急性白血病患者MRP、p170与多药耐药关系的分析  

The relationship between MRP, p170 expression and MDR in acute leukemia

作　　者：赵瑜[1] 于力[1] 楼方定[1] 浦津[1] 王永平[1] 史子江[1] 靳海杰[1] 

机构地区：[1]解放军总医院血液科,北京100853

出　　处：《军医进修学院学报》2000年第1期48-50,共3页Academic Journal of Pla Postgraduate Medical School

基　　金："九五"军队医药卫生科研基金!项目( 96 Z0 2 3 )

摘　　要：目的 :评价 p糖蛋白 ( p170 )和多药耐药相关蛋白 ( m ultidrug resistance- associated protein,MRP)表达与急性白血病患者多药耐药的关系。方法 :将急性白血病患者按治疗效果分为初治敏感组、完全缓解组和复发难治组三组 ,用免疫细胞化学结合流式细胞仪测定 p170和 MRP。结果 :p170在各型白血病中完全缓解组均低于初治和复发难治组 ,MRP在 AML 中复发难治组明显高于完全缓解组 ;复发难治组 3 5人中 2 7例有上述两或一种蛋白表达增高 ,两者均与临床耐药相关。综合分析敏感性、特异性和准确性 ,以 p170和 MRP联合评价效果最佳。结论 :急性白血病多药耐药的发生是多因素的 ,p170和Objective:To evaluate the relationship between MRP, p170 expression and MDR in acute leukemia patients. Methods:83 patients were divided into three groups: untreated (A), complete remission (B) and relapsed/refractory (C), detected their MRP and p170 expression by immunocytochemistry and FACS. Results: p170 expression was lower in B group than in A and C groups in AML and ALL, MRP expression in AML was higher in C group than in B group; there were 27 of 35 patients expressed one or two proteins in C group; The combination of p170 and MRP detection turned out to be a more sensitive, speculiar and accurate way in evaluation of MDR. Conclusion:clinical MDR is multifactorial, p170 and MRP are all associatd with it.

关 键 词：急性白血病 P糖蛋白 MRP 多药耐药性 

分 类 号：R733.710.2[医药卫生—肿瘤]